Targeting the renin-angiotensin-aldosterone system in heart failure

    Research output: Contribution to journalArticle

    52 Citations (Scopus)

    Abstract

    The renin-angiotensin-aldosterone system is a well-established therapeutic target in the treatment of heart failure (HF). Substantial advances have been made with existing agents-angiotensin-converting enzyme (ACE) inhibitors, angiotensin II-receptor blockers (ARBs), and mineralocorticoid-receptor antagonists (MRAs)-and new data continue to emerge. The indication for the use of MRAs has been broadened to include potentially all patients who have HF with reduced ejection fraction (HFrEF), and ACE inhibitors might have a novel application in patients who are at risk of left ventricular dysfunction (those with aortic valvular disease or pacing-induced heart disease). ARBs have been shown to be a beneficial alternative to ACE inhibitors in HFrEF, but their value when added to ACE inhibitors has been questioned. Upstream, direct renin blockade with aliskiren is being pursued in two large trials of HF, despite the premature halting of a third study. A substantial, unmet need remains in patients who have HF with preserved ejection fraction (HFpEF). New data on spironolactone and LCZ696 (a combined ARB and neprilysin inhibitor) show promise for these patients. Results of the TOPCAT study of spironolactone in patients with HFpEF are awaited, and LCZ696 is now being tested in a large trial in patients with HFrEF.
    Original languageEnglish
    Pages (from-to)125-134
    Number of pages10
    JournalNature reviews. Cardiology
    Volume10
    Early online date15 Jan 2013
    DOIs
    Publication statusPublished - Mar 2013

    Fingerprint

    Renin-Angiotensin System
    Heart Failure
    Angiotensin-Converting Enzyme Inhibitors
    Angiotensin Receptor Antagonists
    Mineralocorticoid Receptor Antagonists
    Spironolactone
    Neprilysin
    Aortic Diseases
    Left Ventricular Dysfunction
    Treatment Failure
    Renin
    Heart Diseases

    Cite this

    @article{cc1aee0557ec44b9ba31faef118fa3fe,
    title = "Targeting the renin-angiotensin-aldosterone system in heart failure",
    abstract = "The renin-angiotensin-aldosterone system is a well-established therapeutic target in the treatment of heart failure (HF). Substantial advances have been made with existing agents-angiotensin-converting enzyme (ACE) inhibitors, angiotensin II-receptor blockers (ARBs), and mineralocorticoid-receptor antagonists (MRAs)-and new data continue to emerge. The indication for the use of MRAs has been broadened to include potentially all patients who have HF with reduced ejection fraction (HFrEF), and ACE inhibitors might have a novel application in patients who are at risk of left ventricular dysfunction (those with aortic valvular disease or pacing-induced heart disease). ARBs have been shown to be a beneficial alternative to ACE inhibitors in HFrEF, but their value when added to ACE inhibitors has been questioned. Upstream, direct renin blockade with aliskiren is being pursued in two large trials of HF, despite the premature halting of a third study. A substantial, unmet need remains in patients who have HF with preserved ejection fraction (HFpEF). New data on spironolactone and LCZ696 (a combined ARB and neprilysin inhibitor) show promise for these patients. Results of the TOPCAT study of spironolactone in patients with HFpEF are awaited, and LCZ696 is now being tested in a large trial in patients with HFrEF.",
    author = "Lang, {Chim C.} and Struthers, {Allan D.}",
    year = "2013",
    month = "3",
    doi = "10.1038/nrcardio.2012.196",
    language = "English",
    volume = "10",
    pages = "125--134",
    journal = "Nature reviews. Cardiology",
    issn = "1759-5002",
    publisher = "Nature Publishing Group",

    }

    Targeting the renin-angiotensin-aldosterone system in heart failure. / Lang, Chim C.; Struthers, Allan D.

    In: Nature reviews. Cardiology, Vol. 10, 03.2013, p. 125-134.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Targeting the renin-angiotensin-aldosterone system in heart failure

    AU - Lang, Chim C.

    AU - Struthers, Allan D.

    PY - 2013/3

    Y1 - 2013/3

    N2 - The renin-angiotensin-aldosterone system is a well-established therapeutic target in the treatment of heart failure (HF). Substantial advances have been made with existing agents-angiotensin-converting enzyme (ACE) inhibitors, angiotensin II-receptor blockers (ARBs), and mineralocorticoid-receptor antagonists (MRAs)-and new data continue to emerge. The indication for the use of MRAs has been broadened to include potentially all patients who have HF with reduced ejection fraction (HFrEF), and ACE inhibitors might have a novel application in patients who are at risk of left ventricular dysfunction (those with aortic valvular disease or pacing-induced heart disease). ARBs have been shown to be a beneficial alternative to ACE inhibitors in HFrEF, but their value when added to ACE inhibitors has been questioned. Upstream, direct renin blockade with aliskiren is being pursued in two large trials of HF, despite the premature halting of a third study. A substantial, unmet need remains in patients who have HF with preserved ejection fraction (HFpEF). New data on spironolactone and LCZ696 (a combined ARB and neprilysin inhibitor) show promise for these patients. Results of the TOPCAT study of spironolactone in patients with HFpEF are awaited, and LCZ696 is now being tested in a large trial in patients with HFrEF.

    AB - The renin-angiotensin-aldosterone system is a well-established therapeutic target in the treatment of heart failure (HF). Substantial advances have been made with existing agents-angiotensin-converting enzyme (ACE) inhibitors, angiotensin II-receptor blockers (ARBs), and mineralocorticoid-receptor antagonists (MRAs)-and new data continue to emerge. The indication for the use of MRAs has been broadened to include potentially all patients who have HF with reduced ejection fraction (HFrEF), and ACE inhibitors might have a novel application in patients who are at risk of left ventricular dysfunction (those with aortic valvular disease or pacing-induced heart disease). ARBs have been shown to be a beneficial alternative to ACE inhibitors in HFrEF, but their value when added to ACE inhibitors has been questioned. Upstream, direct renin blockade with aliskiren is being pursued in two large trials of HF, despite the premature halting of a third study. A substantial, unmet need remains in patients who have HF with preserved ejection fraction (HFpEF). New data on spironolactone and LCZ696 (a combined ARB and neprilysin inhibitor) show promise for these patients. Results of the TOPCAT study of spironolactone in patients with HFpEF are awaited, and LCZ696 is now being tested in a large trial in patients with HFrEF.

    U2 - 10.1038/nrcardio.2012.196

    DO - 10.1038/nrcardio.2012.196

    M3 - Article

    VL - 10

    SP - 125

    EP - 134

    JO - Nature reviews. Cardiology

    JF - Nature reviews. Cardiology

    SN - 1759-5002

    ER -